The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 11, 2022

Filed:

Oct. 19, 2017
Applicants:

The Governing Council of the University of Toronto, Toronto, CA;

Mcmaster University, Hamilton, CA;

Inventors:

Jason Moffat, Toronto, CA;

Jarrett Adams, Toronto, CA;

Guohua Pan, Oakville, CA;

Sachdev Sidhu, Toronto, CA;

Rashida Williams, Mississauga, CA;

Xiaoyu Zhang, Toronto, CA;

Sheila K. Singh, Hamilton, CA;

Parvez Vora, Hamilton, CA;

Chitra Venugopal, Burlintong, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 35/17 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2809 (2013.01); C07K 16/468 (2013.01); G01N 33/57407 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01);
Abstract

This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.


Find Patent Forward Citations

Loading…